ExpiresAugust 7, 2022
Louisiana Medical Mutual Insurance Company (LAMMICO)
“Off-label use” is not a phrase that many patients have heard from prescribing practitioners but, when there has been an untoward effect, it has led to claims of malpractice. Many drugs and devices commonly prescribed are used off-label (as defined by the FDA) but this fact is not often disclosed to patients. Legal and ethical considerations for disclosure of FDA status and patient consent are examined in this education to help guide the practitioner.
Correct answers to the post-test; Comparative performance to peers; Recommended literature or other resources (presentations, audio/video, checklists, etc.); Post-activity follow up
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
Psychiatry and Neurology
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Prior to prescribing drugs or devices for purposes that are considered "off-label use," both legal and ethical considerations will be used to determine the extent of disclosure and patient consent necessary
Consent, Off-Label, Prescribing, Drugs, Devices, FDA, Disclosure, Medical Ethics, Ethics, Informed Consent, Off-Label Use, Materiality, FDA Approval
Interpersonal & Communication Skills, Patient Care & Procedural Skills, Professionalism
CME Credit Type
AMA PRA Category 1 Credit
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
National Quality Strategies and/or Quadruple Aim Care Processes
Physician-Patient Relationship, Medical Ethics